- Condition: Peripheral Artery Disease
Intervention: Device: electrical muscle stimulation
Sponsors: University Hospital, Angers; University Hospital, Angers
Recruiting - verified May 2012 - Condition: Mild to Moderate Psoriasis
Interventions: Other: TTOP; Other: non-TTOP
Sponsors: Reich, Kristian, M.D.; Kristian Reich, MD; LEO Pharma
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer Starting a Third Line Chemotherapy
Intervention: Other: Construction of a prognostic score (non-drug intervention types)
Sponsors: Institut Claudius Regaud; Institut Claudius Regaud
Not yet recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Diphtheria; Tetanus; Poliomyelitis
Intervention: Biological: Diphtheria, tetanus, polio and pertussis vaccination
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD
Recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Procedure: Spirometry
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Lymphocytic Leukemia, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Ulcerative Colitis
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals; ANGH: Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux de France; CREGG: Club de Réflexion des Cabinets et Groupes d'Hépato-Gastroentérologie
Recruiting - verified May 2012 - Condition: Cancer
Interventions: Radiation: First part of treatment : Conformal irradiation; Procedure: Fiducials placement; Radiation: Second part : hypofractionated stereotactic boost
Sponsors: Centre Oscar Lambret; Centre Oscar Lambret
Recruiting - verified May 2012 - Conditions: Port Wine Stain; Klippel Trenaunay Syndrome; Parkes Weber Syndrome
Intervention: Genetic: search for polymorphisms of RASA1 gene
Sponsors: University Hospital, Tours; University Hospital, Tours
Recruiting - verified June 2011 - Condition: RHABDOMYOSARCOMA
Interventions: Drug: Vincristine, Irinotecan; Drug: Vincristine-Irinotecan-Temozolomide
Sponsors: Centre Oscar Lambret; Centre Oscar Lambret; SFCE
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Soft Tissue Sarcoma
Interventions: Drug: Eribulin mesylate 1.4 mg/m2 intravenous; Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012 - Conditions: Myelodysplastic Syndrome,; Transfusional Iron Overload
Intervention: Drug: Deferasirox
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Visual Impairment; Macular Edema
Intervention: Drug: ranibizumab
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Indacaterol 150 µg once-daily via single-dose dry powder inhaler
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012 - Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Neoplasms, Breast; WT1-positive Primary Invasive Breast Cancer
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012 - Condition: Venous Thromboembolism
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Renal Interstitial Fibrosis
Interventions: Drug: Everolimus + enteric-coated mycophenolate sodium + Steroids; Drug: Cyclosporine A+EC-MPA+steroids
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech; German CLL Study Group
Recruiting - verified April 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Arthroplasty, Replacement; Thromboembolism
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAIONCondition: Optic Neuropathy, Ischemic
Intervention: Drug: No intervention
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Hemiplegia
Interventions: Behavioral: physical therapy sessions; Behavioral: physical therapy sessions
Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Centre Hospitalier Universitaire de Saint Etienne; Ministry of Health, France
Recruiting - verified May 2012 - Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2010 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012 - Conditions: Pulmonary Embolism; Venous Thrombosis
Interventions: Device: ALN optional filter; Device: No ALN optional filter
Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Centre Hospitalier Universitaire de Saint Etienne; Ministry of Health, France; Fondation de France; Fondation de l'Avenir; ALN Implants Company; Agence Nationale pour la Recherche
Recruiting - verified May 2012
 |
Join Clinical Trials that are Held in Angers, France |
Clinical Trial Locations 